Question · asked by 1 review
Summary of findings table ‐ Continuation vs reduction of polypharmacy: Quality of life: clinically important change ‐ not measured
- Population
- patients with schizophrenia
- Intervention
- Summary of findings table ‐ Continuation
- Comparison
- reduction of polypharmacy
- Outcome
- Quality of life: clinically important change ‐ not measured
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings table ‐ Continuation vs reduction of polypharmacy Quality of life: clinically important change ‐ not reported · people with schizophrenia The review found no eligible studies for this question. Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia (2022) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.